HCW Biologics Inc. (NASDAQ: HCWB) saw its shares move up the chain Wednesday. The company a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, was granted U.S. Patent No. 11,672,826 on June 13, which contains methods of use claims directed to administering the Company’s clinical-stage bifunctional immunotherapeutic, HCW9218, to treat all kinds of cancers.
This includes colorectal cancer, breast cancer, ovarian cancer, hepatocellular carcinoma, gastric cancer, urothelial carcinoma, and melanoma. The patent also includes methods of use claims for killing or reducing the number of senescent cells by administering HCW9218 in subjects with cancer. Senescence is considered a physiologic process that is important in promoting wound healing, regeneration, and many other vital functions. However, stressors cause accumulation of senescent cells which modifies the microenvironment in tissues and organs and creates chronic, sterile inflammation, which drives aging and age-related diseases.
This patent further strengthens the Company’s position as a leader in the emerging field of inflammaging.
CEO Hing Wong said, “This patent supports our commitment to treat diseases driven by chronic inflammation typical of aging and age-related diseases, including cancer. These diseases are promoted by cellular senescence and the proinflammatory factors they secrete, known as SASP factors.”
HCWB shares took on nine cents, or 4.5%, to $2.10.
